ARID1A is altered in 23.11% of malignant ovarian endometrioid tumor patients [2].

ARID1A is an inclusion eligibility criterion in 1 clinical trial for malignant ovarian endometrioid tumor, of which 0 are open and 1 is closed. Of the trial that contains ARID1A status and malignant ovarian endometrioid tumor as inclusion criteria, 1 is phase 1 (0 open) [3].

KDM6A is altered in 4.91% of malignant ovarian endometrioid tumor patients [2].

KDM6A is an inclusion eligibility criterion in 1 clinical trial for malignant ovarian endometrioid tumor, of which 0 are open and 1 is closed. Of the trial that contains KDM6A status and malignant ovarian endometrioid tumor as inclusion criteria, 1 is phase 1 (0 open) [3].

KMT2C is altered in 7.83% of malignant ovarian endometrioid tumor patients [2].

KMT2C is an inclusion eligibility criterion in 1 clinical trial for malignant ovarian endometrioid tumor, of which 0 are open and 1 is closed. Of the trial that contains KMT2C status and malignant ovarian endometrioid tumor as inclusion criteria, 1 is phase 1 (0 open) [3].

KMT2D is altered in 12.23% of malignant ovarian endometrioid tumor patients [2].

KMT2D is an inclusion eligibility criterion in 1 clinical trial for malignant ovarian endometrioid tumor, of which 0 are open and 1 is closed. Of the trial that contains KMT2D status and malignant ovarian endometrioid tumor as inclusion criteria, 1 is phase 1 (0 open) [3].

SMARCA2 is an inclusion eligibility criterion in 1 clinical trial for malignant ovarian endometrioid tumor, of which 0 are open and 1 is closed. Of the trial that contains SMARCA2 status and malignant ovarian endometrioid tumor as inclusion criteria, 1 is phase 1 (0 open) [3].

SMARCA4 is altered in 4.35% of malignant ovarian endometrioid tumor patients [2].

SMARCA4 is an inclusion eligibility criterion in 1 clinical trial for malignant ovarian endometrioid tumor, of which 0 are open and 1 is closed. Of the trial that contains SMARCA4 status and malignant ovarian endometrioid tumor as inclusion criteria, 1 is phase 1 (0 open) [3].

SMARCB1 is altered in 2.37% of malignant ovarian endometrioid tumor patients [2].

SMARCB1 is an inclusion eligibility criterion in 1 clinical trial for malignant ovarian endometrioid tumor, of which 0 are open and 1 is closed. Of the trial that contains SMARCB1 status and malignant ovarian endometrioid tumor as inclusion criteria, 1 is phase 1 (0 open) [3].

SS18 is altered in 1.42% of malignant ovarian endometrioid tumor patients [2].

SS18 is an inclusion eligibility criterion in 1 clinical trial for malignant ovarian endometrioid tumor, of which 0 are open and 1 is closed. Of the trial that contains SS18 status and malignant ovarian endometrioid tumor as inclusion criteria, 1 is phase 1 (0 open) [3].

SSX1 is an inclusion eligibility criterion in 1 clinical trial for malignant ovarian endometrioid tumor, of which 0 are open and 1 is closed. Of the trial that contains SSX1 status and malignant ovarian endometrioid tumor as inclusion criteria, 1 is phase 1 (0 open) [3].

SSX2 is an inclusion eligibility criterion in 1 clinical trial for malignant ovarian endometrioid tumor, of which 0 are open and 1 is closed. Of the trial that contains SSX2 status and malignant ovarian endometrioid tumor as inclusion criteria, 1 is phase 1 (0 open) [3].

SSX2B is an inclusion eligibility criterion in 1 clinical trial for malignant ovarian endometrioid tumor, of which 0 are open and 1 is closed. Of the trial that contains SSX2B status and malignant ovarian endometrioid tumor as inclusion criteria, 1 is phase 1 (0 open) [3].

SSX4 is an inclusion eligibility criterion in 1 clinical trial for malignant ovarian endometrioid tumor, of which 0 are open and 1 is closed. Of the trial that contains SSX4 status and malignant ovarian endometrioid tumor as inclusion criteria, 1 is phase 1 (0 open) [3].